Biohit Oyj - Company Announcement

Biohit Oyj to offer holders of convertible bonds possibility to sell loan back to company

31 January 2012 11:00 AM


Biohit Oyj
Stock exchange release
31 January 2012


The Board of Directors of Biohit Oyj has decided at the Board meeting that the
company will offer holders of Biohit Oyj convertible bonds to possibility to
sell loan back to the company. On 14 December 2011, Biohit Oyj sold its liquid
handling business to Sartorius Lab Holding GmbH, and with this sale the
financial standing of the company has become significantly stronger. 

On 28 October 2010, Biohit Oyj issued a convertible bond targeted at
institutional investors. The value at the moment of issue was 4.05 million. The
fixed coupon rate of the bond is 6.5% and it has a five-year maturity. Each
share of the loan of EUR 4,500 entitles the holder to exchange the share of the
loan for 1,000 B shares with a nominal value of EUR 0.17. The rate of exchange
of the share is EUR 4.5. The loan can be exchanged for a maximum of 900,000
shares of Biohit Oyj. 

Biohit Oyj offers investors in the convertible bond the possibility to sell
their loan at its value on 1 February 2012 (the date when the loan will be
purchased back). The investors will be paid the nominal capital of the loan and
the interest accrued. 



For further details, contact:
Semi Korpela
President and CEO
Tel. +358 40 573 7701
semi.korpela@biohit.fi


Distribution:
NASDAQ
OMX Helsinki Oyj
Central Storage Facility (www.oam.fi)
Press
www.biohit.fi

About Biohit
Biohit Oyj is a globally operating Finnish biotechnology company established in
1988. Biohit's mission crystallizes in its motto “Innovating for Health”. The
company assumes social responsibility by producing innovations, new
technologies and analysis systems for use in medicine, research institutions
and industry. These products help to promote research and diagnostics, while
improving quality of life by preventing disease, human suffering and financial
loss. Biohit also seeks to innovate and develop the marketing and availability
of its products and services, in order to ensure its profitable growth and
ability to pay dividends. 

Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations. These can be used to
develop safe and cost-effective diagnostic tests for the early detection and
prevention of diseases of the gastrointestinal tract. (www.biohit.fi /
International / State of the art GastroPanel and Acetium innovations for the
unmet need) 

Biohit's products include analysis systems for the prevention and early
diagnosis of gastrointestinal diseases, such as the blood-sample based
GastroPanel examinations for the diagnosis of stomach illnesses and associated
risks, quick tests for the diagnosis of lactose intolerance and H. pylori
infection in connection with gastroscopy, and the ColonView examination for the
early detection of intestinal bleeding that indicates a risk of colorectal
cancer. Acetium reduces the amount of carcinogenic acetaldehyde in an anacidic
stomach. (www.acetium.com/test - reveals acetaldehyde exposure) 

Biohit employs around 35 people. The company is headquartered in Helsinki,
Finland and has a subsidiary in the UK. Since 1999, Biohit's Series B share
(BIOBV) has been quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare
group and is traded under the code BIOBV (www.biohit.fi). 

Read more at www.biohit.fi